Fibrilación auricular de causa no valvular: Indicaciones de terapia antitrombótica

Medicina Clinica

Volumn 106, Issue 15, 1996, Pages 586-589

  Huix, Pedro Codinach ^a  

^a Hospital Cruz Roja   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; WARFARIN;

AGED; BLEEDING; CEREBROVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; MIDDLE AGED; REVIEW; RISK FACTOR;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; EMBOLISM; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; WARFARIN;

EID: 0007380947     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lake FR, Cullen KJ, De Klerk NH Atrial fibrillation and mortality in an elderly population. Aust NZ J Med 1989; 19. 321-326
2. Rayo I, Martin Huerta E. La fibrilación auricular sin obstáculo mitral: ¿anticoagulación crónica? Argumentos en contra. Rev Esp Cardiol 1994; 47: 276-283.
3. Sagristá Sauleda J. La fibrilación auricular sin obstáculo mitral, ¿anticoagulactón crónica? Argumentos a favor. Rev Esp Cardiol 1994, 47: 269-275.
4. Kopecky SL, Gersh BJ, McGoon MD, Wihsnant JP, Holmes DR, Ilstrup DM et al. The natural history of lone atrial fibrillation: A population-based study over three decades. N Engl J Med 1987; 317. 669-674.
5. Onundarson PT, Thorgeirsson G, Jonmudson E, Sigfusson N, Hardarson TH. Chronic atrial fibrillation-Epidemiologic features and 14-year follow-up: a case control study. Eur Heart J 1987; 3: 521-527
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke, the Framingham Study. Stroke 1991; 22: 983-988.
7. Feinberg WM, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Intern Med 1990; 150: 2.340-2.344.
8. White HD. Aspirin or warfarin for non-rheumatic atrial fibrillation? Lancet 1994; 343. 683-684.
9. Fuster V, Dyken ML, Vokonas PS. Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease Special Writing Group Circulation 1993; 87: 659-675.
10. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation the Copenhagen AFASAK study. Lancet 1989; 1: 175-178
11. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation N Engl J Med 1990; 323: 1 505-1.511.
12. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J Am Coll Cardiol 1991; 18: 349-355.
13. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527-539.
14. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992, 327. 1 406-1 412.
15. Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet 1994; 343: 687-691.
16. Singer DE, Hughes RA, Gres DR, Sheeham MA, Oertel LB, Marcventano SW et al. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study Am Heart J 1992; 124: 1.567-1.573.
17. Analysis of Pooled Data From Five Randomized Controlled Trials. Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation Arch Intern Med 1994; 154: 1.449-1.457
18. The Stroke Prevention in Atrial Fibrillation Investigators. Predicting of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med 1992; 116. 1-5.
19. Stroke Prevention in Atrial Fibrillation Investigators. Prediction of thromboembolism in atrial fibrillation, II: echocardiographic features of patients ar risk. Ann Intern Med 1992, 116: 6-12.
20. Cairns JA Prevención de la embolia sistémica en pacientes con fibrilación auricular En Ezekowitz MD, editor. Tratamiento anticoagulante y antiplaquetario, y enferrnedad cardiovascular. Clínicas Cardiológicas de Norteamérica. México. Editorial Interaméricana. McGraw-Hill, 1994, 3. 527-536.
21. Fihn SD. Aiming for safe anticoagulation. N Engl J Med 1995, 333 54-55
22. Gayán Laviña R, Luengo Fernández E, Gracia Balaguer FJ, Villacampa Guío S. Fibrilación auricular no reumática y tratamiento antitrombótico. estado actual Rev Clin Esp 1995, 195: 559-564.
23. The European Atrial Fibrillation Trial Study Group Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia N Engl J Med 1995, 333: 5-10.
24. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J Am Coll Cardiol 1992; 19: 851-855.
25. Black IW, Hopkins AP, Lee LC, Walsh WF Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoaguled patients. Am Heart J 1993; 126: 375-381.